Quantcast
Last updated on April 16, 2014 at 14:14 EDT

Latest Trastuzumab Stories

2013-11-13 13:23:44

Phase III trial examines pathological complete response rate Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research from Aman Buzdar M.D., professor and vice president of clinical research at The University of Texas MD Anderson Cancer Center, and colleagues in the Alliance for Clinical Trials in Oncology, shows these...

2013-11-08 08:27:57

SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter and nine months ended September 30, 2013. Financial highlights for the third quarter include revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share. This compares to revenues of $5.3 million and a net loss of $20.0 million, or $0.18 per share, for the third quarter of 2012. (Logo:...

2013-11-07 23:30:39

RnRMarketResearch.com adds Latest Report on “Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth” to its store. Dallas, TX (PRWEB) November 07, 2013 The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of...

2013-11-07 12:27:09

Interviewed Payers Indicate that Budget Constraints May Also Drive Uptake of Trastuzumab Biosimilars over Branded Herceptin, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed medical oncologists across the EU5 (France, Germany, Italy, Spain and the United Kingdom) currently prescribe Roche/Genentech's...

2013-10-31 08:33:35

However, Changes in Treatment Practices Via Improved Originator Biologics Threaten Biosimilar Uptake, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European oncologists will cautiously adopt biosimilar monoclonal antibodies initially; only a minority of oncologists say they will...

2013-10-15 11:17:03

An optical imaging technique that measures metabolic activity in cancer cells can accurately differentiate breast cancer subtypes, and it can detect responses to treatment as early as two days after therapy administration, according to a study published in Cancer Research, a journal of the American Association for Cancer Research. "The process of targeted drug development requires assays that measure drug target engagement and predict the response (or lack thereof) to treatment," said Alex...

2013-10-14 08:25:25

Prime Therapeutics analysis finds nearly 76 percent of patients taking Herceptin were treated in early stage breast cancer - important for predicting breast cancer future costs ST. PAUL, Minn., Oct. 14, 2013 /PRNewswire/ -- Expanded use of the common breast cancer drug Herceptin® (trastuzumab) can be tracked using pharmacy and medical administrative claims data, according to a new analysis by pharmacy benefit manager Prime Therapeutics LLC (Prime). Prime will be presenting the study...

2013-10-07 16:25:28

Leading Health Care Organizations Recommend to Test All Patients with Invasive Breast Cancer for HER2 Status NORTHFIELD, Ill., Oct. 7, 2013 /PRNewswire-USNewswire/ -- The College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO) today issued a joint, updated guideline aimed at improving the accuracy and reporting of human epidermal growth factor receptor 2 (HER2) testing in patients with invasive breast cancer. The guideline update is based on a systematic...

2013-10-07 08:25:26

SEATTLE, WA, Oct. 7, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of final results from the first Phase 1 trial of ONT-380 at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research in San Diego. The results were presented by Virginia F. Borges, M.D., Associate Professor in the Division of Medical Oncology, University of Colorado School of Medicine. ONT-380 (also known as ARRY-380) is an orally...

2013-09-26 16:27:00

SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the commercial launch of Herceptin(®) SC in Europe has triggered a $10 million milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche. This time-saving subcutaneous formulation of Herceptin (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) received marketing authorization from the European Commission on August...